Silver nanoparticles (AgNPs) are increasingly recognized as vital nanomaterials in biomedical applications due to their
diverse pharmacological properties, including antimicrobial and anti-neoplastic effects, particularly when derived from
herbal sources. This study aims to synthesize AgNPs employing a sustainable approach aligned with the principles of the
sustainable development goals. The synthesized AgNPs are incorporated with doxorubicin (DOX) and encapsulated within
polylactide nanoparticles to enhance their anticancer potency. AgNPs are prepared via the reduction of silver ions using
rutin as a reducing agent, with the reaction progress monitored via ultraviolet-visible spectroscopy (UV-vis). Subsequently,
the AgNPs are encapsulated into poly(D, L-lactic acid) (PDLLA) nanoparticles alongside doxorubicin. The developed
nanoparticles have shown a diameter size of 233 nm with a zeta potential of -21.47 mV. Moreover, the in vitro release
profile of the DOX showed a sustained release kinetics over 30 h. Evaluation of the AgNP-DOX-loaded PDLLA nanoparticles
reveals enhanced anticancer activity against HeLa and HepG2 cancer cells, highlighting the synergistic efficacy of
the combined therapy. These findings underscore the potential of AgNPs-based formulations as promising candidates for
advanced cancer therapeutics.

Title

Journal of Cluster science

Publisher

Springer Nature

Publisher Country

United Kingdom

Indexing

Thomson Reuters

Impact Factor

2.7

Publication Type

Both (Printed and Online)

Volume

35

Year

2024

Pages

2813